MIRM
Mirum Pharmaceuticals, Inc.
$99.35
-0.20%
$6.1B
No data for this timeframe.
Vol
Market Cap$6.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$3.3B
Inst. Activity26 buys / 13 sells
Insider Activity0B / 15S
Insider Net $-$10.0M
Reddit Sentiment50° Neutral
SEC Reports10
Recent Activity
Sep 26, 2026
fda_pdufa
PDUFA: MIRM — zilurgisertib in Fibrodysplasia Ossificans Progressiva — 2026-09-26
FDA target action date 2026-09-26 for MIRM (Mirum Pharmaceuticals, Inc.). Drug: zilurgisertib. Indic
Jun 11, 2026
SEC
A strong institutional buying cluster emerged in MIRM during Q4 2025, with 9 buyers adding $189.1M in net new positions
INST-CLUSTER — Impact 6/10
Jun 10, 2026
SEC
Three Mirum insiders, including the CEO and CFO, sold a total of $854K in open-market sales over a one-week window. The
CLUSTER — Impact 3/10
Jun 9, 2026
Insider
BJERKHOLT ERIC acquired via exercise 2,393 shares
CHIEF FINANCIAL OFFICER @ $26.49 ($63.4K)
Jun 8, 2026
Insider
BJERKHOLT ERIC sold 2,258 shares
CHIEF FINANCIAL OFFICER @ $92.84 ($209.6K)
Jun 5, 2026
Insider
Radovich Peter acquired via exercise 16,988 shares
PRESIDENT AND COO @ $19.19 ($326.0K)
Jun 2, 2026
SEC
Mirum Pharmaceuticals CEO Christopher Peetz and Director Saira Ramasastry sold a combined $644K in open-market sales on
CLUSTER — Impact 2/10
Inst.
FMR LLC — DOUBLED
1,965,375 shares ($181.6M)
Price Targets
$144.93
+45.9% upside
Strong Buy
Current $99.35
Low $115.00
Median $143.50
High $185.00
14 analysts
$115.00
$185.00
Analyst Ratings
7Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Jun 2, 2026 | Citigroup | INITIATE | Buy |
| May 19, 2026 | Wolfe Research | INITIATE | Outperform |
| May 7, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.81 ▼ -87.8% | $-0.94 — $-0.58 | -573% YoY | 4 |
| Next Q | $-0.70 ▼ -58.1% | $-1.06 — $-0.40 | -1505% YoY | 4 |
| Current FY | $-16.33 ▼ -902.7% | $-16.33 — $-16.33 | -3374% YoY | 1 |
| Next FY | $-0.56 ▼ -2725.9% | $-2.44 — $0.70 | 97% YoY | 5 |
Latest Reports
BULLISH
INST-CLUSTER
6/10
A strong institutional buying cluster emerged in MIRM during Q4 2025, with 9 buyers adding $189.1M in net new positions
Jun 11, 2026
NEUTRAL
CLUSTER
3/10
Three Mirum insiders, including the CEO and CFO, sold a total of $854K in open-market sales over a one-week window. The
Jun 10, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| JANUS HENDERSON GROUP PLC | $627.3M | — |
| BlackRock, Inc. | $355.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $223.1M | — |
| FMR LLC | $181.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | BJERKHOLT ERIC | M | $63.4K |
| Jun 8, 2026 | BJERKHOLT ERIC | SELL | $209.6K |
| Jun 5, 2026 | Radovich Peter | M | $326.0K |
| Jun 1, 2026 | Peetz Christopher | SELL | $246.3K |
| Jun 1, 2026 | Peetz Christopher | M | $88.1K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $3.3B total value (36,009,911 shares) as of 2026-Q1. Top holders: NOMURA, JANUS, BlackRock,. Net buying activity: 26 institutions added/increased vs 13 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | JANUS HENDERSON GROUP PLC | 6,789,239 | $627.3M | 18.9% | — |
| 3 | BlackRock, Inc. | 3,846,530 | $355.3M | 10.7% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,414,776 | $223.1M | 6.7% | — |
| 5 | FMR LLC | 1,965,375 | $181.6M | 5.5% | DOUBLED +204.0% |
| 6 | STATE STREET CORP | 1,944,281 | $179.6M | 5.4% | ADD +59.2% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,432,083 | $132.3M | 4.0% | — |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 1,334,809 | $123.3M | 3.7% | ADD +56.6% |
| 9 | CITADEL ADVISORS LLC | 1,052,048 | $97.2M | 2.9% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 774,841 | $71.6M | 2.2% | — |
| 11 | Capital World Investors | 724,415 | $66.9M | 2.0% | NEW |
| 12 | BANK OF AMERICA CORP /DE/ | 722,177 | $66.7M | 2.0% | ADD +82.7% |
| 13 | FRANKLIN RESOURCES INC | 714,804 | $66.0M | 2.0% | — |
| 14 | Clearbridge Investments, LLC | 671,870 | $62.1M | 1.9% | — |
| 15 | GOLDMAN SACHS GROUP INC | 662,306 | $61.2M | 1.8% | — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 582,085 | $53.8M | 1.6% | ADD +32.6% |
| 17 | Woodline Partners LP | 567,894 | $52.5M | 1.6% | — |
| 18 | BALYASNY ASSET MANAGEMENT L.P. | 539,031 | $49.8M | 1.5% | ADD +88.6% |
| 19 | MORGAN STANLEY | 524,566 | $48.5M | 1.5% | TRIM -36.5% |
| 20 | FEDERATED HERMES, INC. | 506,211 | $46.8M | 1.4% | ADD +39.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 646,466 | 1,965,375 | +204.0% | $181.6M | 2026-Q1 |
| Capital World Investors | NEW | — | 724,415 | — | $66.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 439,085 | 582,085 | +32.6% | $53.8M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 285,870 | 539,031 | +88.6% | $49.8M | 2026-Q1 |
| BAKER BROS. ADVISORS LP | NEW | — | 445,975 | — | $41.2M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 577,274 | 423,511 | -26.6% | $39.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 190,638 | 346,991 | +82.0% | $32.1M | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 318,554 | — | $29.4M | 2026-Q1 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | NEW | — | 286,406 | — | $26.5M | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 64,951 | 285,236 | +339.2% | $26.4M | 2026-Q1 |
| Polar Capital Holdings Plc | TRIM | 793,642 | 283,484 | -64.3% | $26.2M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | NEW | — | 129,114 | — | $11.9M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 297,950 | 104,099 | -65.1% | $9.6M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 72,194 | 95,555 | +32.4% | $8.8M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 46,078 | 81,109 | +76.0% | $7.5M | 2026-Q1 |
| PICTON MAHONEY ASSET MANAGEMENT | DOUBLED | 1,420 | 74,118 | +5119.6% | $6.8M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEAR_EXIT | 372,511 | 67,885 | -81.8% | $6.3M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 34,114 | 55,693 | +63.3% | $5.1M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 186,712 | 50,045 | -73.2% | $4.6M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 72,943 | 49,160 | -32.6% | $4.5M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 24,126 | 40,025 | +65.9% | $3.7M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 46,206 | 34,106 | -26.2% | $3.2M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | ADD | 23,276 | 33,688 | +44.7% | $3.1M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 19,889 | 27,588 | +38.7% | $2.5M | 2026-Q1 |
| POLEN CAPITAL MANAGEMENT LLC | ADD | 13,360 | 20,531 | +53.7% | $1.9M | 2026-Q1 |
9 unique insiders with 48 transactions. Net insider value: -$10.0M ($0.00 bought, $10.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | EXERCISE | 2,393 | $26.49 | $63.4K |
| Jun 8, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | SELL | 2,258 | $92.84 | $209.6K |
| Jun 5, 2026 | Radovich Peter | PRESIDENT AND COO | EXERCISE | 16,988 | $19.19 | $326.0K |
| Jun 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 2,602 | $94.64 | $246.3K |
| Jun 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | EXERCISE | 30,000 | $2.94 | $88.1K |
| Jun 1, 2026 | Ramasastry Saira | Director | SELL | 3,977 | $100.00 | $397.7K |
| May 29, 2026 | Cardon Lon | Director | EXERCISE | 3,977 | — | — |
| May 29, 2026 | Ramasastry Saira | Director | EXERCISE | 3,977 | — | — |
| May 29, 2026 | Walbert Timothy P | Director | EXERCISE | 3,977 | — | — |
| May 29, 2026 | Fischer Laurent | Director | EXERCISE | 3,977 | — | — |
| May 15, 2026 | Ramasastry Saira | Director | EXERCISE | 2,000 | $23.51 | $47.0K |
| May 15, 2026 | Ramasastry Saira | Director | SELL | 2,000 | $109.47 | $218.9K |
| Apr 15, 2026 | Ramasastry Saira | Director | EXERCISE | 2,000 | $23.51 | $47.0K |
| Apr 15, 2026 | Ramasastry Saira | Director | SELL | 2,000 | $96.90 | $193.8K |
| Mar 16, 2026 | Radovich Peter | PRESIDENT AND COO | SELL | 16,515 | $91.98 | $1.5M |
| Mar 16, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 40,985 | $91.98 | $3.8M |
| Mar 16, 2026 | Ramasastry Saira | Director | EXERCISE | 2,000 | $23.51 | $47.0K |
| Mar 16, 2026 | Ramasastry Saira | Director | SELL | 2,000 | $90.76 | $181.5K |
| Mar 16, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | SELL | 7,287 | $91.98 | $670.2K |
| Mar 16, 2026 | Quan Joanne | CHIEF MEDICAL OFFICER | SELL | 7,287 | $91.98 | $670.2K |
| Mar 16, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 4,732 | $91.98 | $435.2K |
| Mar 15, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | EXERCISE | 13,334 | — | — |
| Mar 15, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | EXERCISE | 25,000 | — | — |
| Mar 15, 2026 | Radovich Peter | PRESIDENT AND COO | EXERCISE | 7,220 | — | — |
| Mar 15, 2026 | Quan Joanne | CHIEF MEDICAL OFFICER | EXERCISE | 13,334 | — | — |
| Mar 15, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | EXERCISE | 2,658 | — | — |
| Mar 6, 2026 | Radovich Peter | PRESIDENT AND COO | EXERCISE | 5,912 | $15.87 | $93.8K |
| Feb 13, 2026 | Ramasastry Saira | Director | EXERCISE | 2,000 | $23.51 | $47.0K |
| Feb 13, 2026 | Ramasastry Saira | Director | SELL | 2,000 | $102.09 | $204.2K |
| Feb 2, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 968 | $103.30 | $100.0K |
| Feb 2, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 9,108 | $103.30 | $940.9K |
| Feb 2, 2026 | Radovich Peter | PRESIDENT AND COO | SELL | 2,631 | $103.30 | $271.8K |
| Jan 31, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | EXERCISE | 1,771 | — | — |
| Jan 28, 2026 | Radovich Peter | PRESIDENT AND COO | AWARD | 34,500 | — | — |
| Jan 28, 2026 | Radovich Peter | PRESIDENT AND COO | AWARD | 16,280 | — | — |
| Jan 28, 2026 | Radovich Peter | PRESIDENT AND COO | AWARD | 25,120 | — | — |
| Jan 28, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | AWARD | 75,000 | — | — |
| Jan 28, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | AWARD | 43,500 | — | — |
| Jan 28, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | AWARD | 67,000 | — | — |
| Jan 28, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | AWARD | 20,000 | — | — |
| Jan 28, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | AWARD | 18,140 | — | — |
| Jan 28, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | AWARD | 11,760 | — | — |
| Jan 28, 2026 | Quan Joanne | CHIEF MEDICAL OFFICER | AWARD | 18,140 | — | — |
| Jan 28, 2026 | Quan Joanne | CHIEF MEDICAL OFFICER | AWARD | 11,760 | — | — |
| Jan 28, 2026 | Quan Joanne | CHIEF MEDICAL OFFICER | AWARD | 20,000 | — | — |
| Jan 28, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | AWARD | 7,680 | — | — |
| Jan 28, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | AWARD | 4,970 | — | — |
| Jan 28, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | AWARD | 9,000 | — | — |
10 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 4.6/10.
BULLISH
INST-CLUSTER
6/10
A strong institutional buying cluster emerged in MIRM during Q4 2025, with 9 buyers adding $189.1M i
Jun 11, 2026
NEUTRAL
CLUSTER
3/10
Three Mirum insiders, including the CEO and CFO, sold a total of $854K in open-market sales over a o
Jun 10, 2026
NEUTRAL
CLUSTER
2/10
Mirum Pharmaceuticals CEO Christopher Peetz and Director Saira Ramasastry sold a combined $644K in o
Jun 2, 2026
NEUTRAL
144
3/10
Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of inte
Jun 1, 2026
NEUTRAL
144
2/10
Director Saira Ramasastry filed a Form 144 notice of intent to sell 3,977 shares of Mirum Pharmaceut
Jun 1, 2026
MIXED
8-K
6/10
Mirum issued $690.0M of 0.00% convertible senior notes due 2032, including the full $90M greenshoe.
May 18, 2026
BULLISH
8-K
6/10
Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary
May 4, 2026
BULLISH
8-K
8/10
Mirum Pharmaceuticals announced positive Phase 2b results for brelovitug in treating chronic hepatit
Apr 27, 2026
NEUTRAL
144
2/10
Saira Ramasastry, a director at Mirum Pharmaceuticals, filed a Form 144 to notify the sale of 2,000
Apr 15, 2026
BULLISH
8-K
8/10
Mirum Pharmaceuticals reported strong 2025 financial results with $521.3 million in net product sale
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (95% buy). Based on 19 analysts: 7 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$144.93 mean target
+45.9% upside
Strong Buy (1.29)
$115.00 Low
$185.00 High
| Metric | Value |
|---|---|
| Current Price | $99.35 |
| Target Low | $115.00 |
| Target Mean | $144.93 |
| Target Median | $143.50 |
| Target High | $185.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.81 | $-0.94 | $-0.58 | -572.9% | -87.8% | 0↑ 1↓ | $0.2B | 30.0% | 4 |
| Next Q 2026-09-30 |
$-0.70 | $-1.06 | $-0.40 | -1505.0% | -58.1% | 0↑ 2↓ | $0.2B | 29.3% | 4 |
| Current FY 2026-12-31 |
$-16.33 | $-16.33 | $-16.33 | -3374.5% | -902.7% | 0↑ 1↓ | $0.7B | 29.5% | 1 |
| Next FY 2027-12-31 |
$-0.56 | $-2.44 | $0.70 | 96.6% | -2725.9% | 1↑ 1↓ | $0.8B | 20.4% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.807 | |
| 7d ago | $-0.807 | |
| 30d ago | $-0.430 | -0.378 |
| 60d ago | $-0.457 | -0.351 |
| 90d ago | $-0.457 | -0.351 |
11 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jun 2, 2026 | Citigroup | INITIATE | — | Buy |
| May 19, 2026 | Wolfe Research | INITIATE | — | Outperform |
| May 7, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 29, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Mar 27, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 4, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 26, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | RBC Capital | INITIATE | — | Outperform |
| Jan 30, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jan 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 19, 2025 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Dec 16, 2025 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Sep 26, 2026
fda_pdufa
PDUFA: MIRM — zilurgisertib in Fibrodysplasia Ossificans Progressiva — 2026-09-26
FDA target action date 2026-09-26 for MIRM (Mirum Pharmaceuticals, Inc.). Drug: zilurgisertib. Indication: Fibrodysplasia Ossificans Progressiva. FDA
Jun 2, 2026
Clinical Trial
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Phase Phase 2 — COMPLETED
May 29, 2026
short_volume
Short Volume: MIRM — 79.9% short (0.5M / 0.6M)
Short: 493,976 | Exempt: 17,874 | TRF Vol: 618,014 | Short Ratio: 79.9% | Off-exchange volume (dark pool + OTC)
May 21, 2026
FDA
CHOLBAM
Supplemental Approval — Labeling — CHOLIC ACID — CAPSULE — ORAL
May 19, 2026
short_volume
Short Volume: MIRM — 61.5% short (0.3M / 0.5M)
Short: 315,578 | Exempt: 12,984 | TRF Vol: 513,041 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: MIRM — 72.9% short (0.4M / 0.5M)
Short: 379,061 | Exempt: 18,136 | TRF Vol: 519,629 | Short Ratio: 72.9% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: MIRM — 74.4% short (0.4M / 0.5M)
Short: 404,223 | Exempt: 61,640 | TRF Vol: 543,143 | Short Ratio: 74.4% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: MIRM — 85.7% short (2.7M / 3.1M)
Short: 2,673,191 | Exempt: 2,610 | TRF Vol: 3,118,550 | Short Ratio: 85.7% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: MIRM — 58.9% short (0.5M / 0.9M)
Short: 529,498 | Exempt: 9,427 | TRF Vol: 899,138 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
MIRM Q1 2026 Earnings After Market Close — 2026-05-06
May 5, 2026
earnings_calendar
MIRM Q1 2026 Earnings After Market Close — 2026-05-05
Apr 30, 2026
earnings_calendar
MIRM Q1 2026 Earnings After Market Close — 2026-04-30
Apr 14, 2026
short_volume
Short Volume: MIRM — 73.0% short (0.4M / 0.5M)
Short: 367,504 | Exempt: 47 | TRF Vol: 503,357 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_interest
FTD: MIRM — 8,831 shares ($0.8M) failed to deliver
Settlement: 20260408, Price: $95.65, FTD Value: $844,685.15, MIRUM PHARMACEUTICALS INC COM
Mar 31, 2026
short_volume
Short Volume: MIRM — 75.8% short (0.5M / 0.7M)
Short: 501,838 | Exempt: 29 | TRF Vol: 662,103 | Short Ratio: 75.8% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_interest
FTD: MIRM — 54,876 shares ($4.8M) failed to deliver
Settlement: 20260331, Price: $87.90, FTD Value: $4,823,600.4, MIRUM PHARMACEUTICALS INC COM
Mar 30, 2026
short_volume
Short Volume: MIRM — 82.7% short (0.5M / 0.5M)
Short: 452,604 | Exempt: 2,850 | TRF Vol: 547,236 | Short Ratio: 82.7% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
Enforcement
1:25-cv-01539 Mirum Pharmaceuticals, Inc. et al v. Zenara Pharma Private Limited et al
Court ruling from United States District Court for the District of Delaware. Docket: N/A